Nontuberculous mycobacterial pulmonary diseases (NTM-PD) are increasingly recognised as opportunistic infections of humans. Nodular/bronchiectatic disease and fibrocavitary disease are the most frequent manifestations . Although guidelines have been published , there are few data on diagnostic and treatment practices outside of reference clinics. A recent survey in the USA suggested limited adherence to guidelines for diagnosis and treatment of NTM-PD .
Poor adherence to diagnosis and treatment guidelines for nontuberculous mycobacterial lung disease in EU and Japan http://ow.ly/EVYl306vVcN
Support statement: This study was initiated and financed by Insmed Incorporated (Bridgewater, NJ, USA). The study was performed by Clarity Pharma Research LLC (Spartanburg, SC, USA) and the NTM-NET (Nontuberculous Mycobacteria Network European Trial Group). Insmed did not influence data acquisition or distribution. This work was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (National Institutes of Health, Bethesda, MD, USA). Funding information for this article has been deposited with the Open Funder Registry.
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
- Received June 13, 2016.
- Accepted November 8, 2016.
- The content of this work is not subject to copyright. Design and branding are copyright ©ERS 2017